Published on 29 Nov 2022 on Zacks via Yahoo Finance
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva Therapeutics plc NBRV announced positive top-line data from the phase I study evaluating its marketed drug, Xenleta (lefamulin), for a new indication.
The phase I study is evaluating the safety and pharmacokinetics (PK) of oral and intravenous (IV) Xenleta for the treatment of adult patients with cystic fibrosis (CF).
Per the company, the data demonstrates PK of Xenleta in CF patients is similar to that seen in previous studies, which evaluated the approved oral and IV dosing of Xenleta for treating adults with community-acquired bacterial pneumonia (CABP).